April 21 (Reuters) - Mauna Kea Technologies SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES PUBLISHES Q1 2022 SALES AND ITS
2021
FINANCIAL RESULTS
* CASH POSITION OF EUR 11.8 MILLION AT END OF 2021 AND TOTAL
LONG-TERM DEBT OF EUR 26,9 MILLION, COMPARED TO EUR 8.6 MILLION
IN CASH AND EUR 26.2 MILLION IN LONG-TERM DEBT, AS OF DECEMBER
31, 2020
* 2021 REVENUES OF EUR 7,700K, UP BY EUR 1,174K, UP +18%
COMPARED
TO 2020
* FY CURRENT OPERATING LOSS OF EUR 11,327K, REDUCED BY EUR
632K
COMPARED TO 2020
* WE ARE ENCOURAGED TO SEE EARLY RETURNS ON OUR RENEWED
EFFORTS TO
BUILD AN EXPANDED PORTFOLIO OF CLINICAL PARTNERS AND
INTELLECTUAL PROPERTY, INCLUDING A NEW COLLABORATION WITH ON
TARGET LABS AND A MAJOR REGULATORY APPROVAL FROM FDA IN FIELD OF
MOLECULAR IMAGING - CEO
* INDICATES THAT IT HAS NO ACTIVITY OR BUSINESS TIES WITH
RUSSIA
OR UKRAINE; HOWEVER, CONSEQUENCES OF THIS CONFLICT, DIRECT OR
INDIRECT, CANNOT BE ACCURATELY QUANTIFIED AT THIS TIME
* HEALTH CRISIS CONTINUED TO NEGATIVELY IMPACT COMPANY'S
BUSINESS
ACTIVITY DURING Q1 OF 2022, PARTICULARLY IN ASIAN MARKETS
* FY OPERATING LOSS EUR 12.2 MLN VERSUS LOSS EUR 11.8
MILLION YEAR
AGO
* FY NET LOSS EUR 13.4 MLN VS LOSS OF EUR 12.8 MLN YEAR AGO
* Q1 SALES EUR 1.9 MLN VS EUR 1.6 MLN YR AGO
Source text for Eikon: urn:newsml:reuters.com:*:nBw2W07SFa
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))